NMG
TEVA icon

New Millennium Group’s Teva Pharmaceuticals TEVA Stock Holding History

New Millennium Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-85
Closed -$752 – 441
2023
Q1 		$752 Hold
85
– – ﹤0.01% 376
2022
Q4 		$775 Hold
85
– – ﹤0.01% 403
2022
Q3 		$1K Hold
85
– – ﹤0.01% 348
2022
Q2 		$1K Buy
+85
New +$741 ﹤0.01% 346

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

New Millennium Group's TEVA Position: Q2 2023 in Review

New Millennium Group sold out of Teva Pharmaceuticals (TEVA) in Q2 2023, closing a stake of 85 shares — an estimated $752 sold.

New Millennium Group first reported a position in TEVA in Q2 2022 and held it in 4 quarters. The position peaked at $1K in Q3 2022. 428 funds tracked by Wall St. Rank hold TEVA as of Q2 2023.

  • New Millennium Group reported no remaining Teva Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • New Millennium Group sold 85 Teva Pharmaceuticals shares in Q2 2023, an estimated $752.
  • New Millennium Group first reported a position in Teva Pharmaceuticals in Q2 2022 and held it in 4 quarters.
  • New Millennium Group's Teva Pharmaceuticals position peaked at $1K in Q3 2022.
  • 428 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2023.

Based on New Millennium Group's 13F filing for Q2 2023, filed 3 Aug 2023.